CompletedNot Applicable

PTRG-DES Consortium

South Korea13,160 participantsStarted 2003-07-09

Plain-language summary

The PTRG-DES consortium is a coalition composed of multi-center, real-world registries including CAD patients treated with DES in South Korea. From 9 academic registries in Korea, a total of 13,160 patients were enrolled for this database between July 2003 and August 2018. The aim of the study was to investigate long-term prognostic implications of platelet function and genotypes after DES implantation for significant CAD in South Korea.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Consecutive patients at every centre successfully treated with one or more DES approved by the US FDA or CE mark and who were adequately loaded with clopidogrel were eligible for enrolment, regardless of patient or lesion complexity. Exclusion Criteria: * the occurrence of a major complication during the procedure or before platelet function testing, or if bypass surgery was planned after PCI. * Any P2Y12 inhibitor other than clopidogrel * PCI strategy other than DES * Needed oral anticoagulant (e.g. atrial fibrillation)

What they're measuring

MACCE

Timeframe: upto 10 years

Trial details

NCT IDNCT04734028

SponsorGyeongsang National University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-08-07

View on ClinicalTrials.gov More Coronary Artery Disease trials